LEADER 03536nam  2200973z- 450 
001 9910557705903321
005 20231214133236.0
035   $a(CKB)5400000000046220
035   $a(oapen)https://directory.doabooks.org/handle/20.500.12854/68421
035   $a(EXLCZ)995400000000046220
100   $a20202105d2021      |y             0
101 0 $aeng
135   $aurmn|---annan
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aComorbidities in Chronic Kidney Disease (CKD)
210   $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021
215   $a1 electronic resource (184 p.)
311   $a3-03936-668-8 
311   $a3-03936-669-6 
330   $aWith a mean worldwide prevalence of 13%, chronic kidney disease imposes a massive health burden on our society. In addition to reduced kidney function, patients with chronic kidney disease increasingly suffer from cardiovascular diseases affecting the heart and vasculature. Cardiovascular diseases account for around half of the deaths of patients with advanced chronic kidney disease. However, therapeutic options are highly insufficient. The pathological mechanisms that underlie increased cardiovascular risk in patients with chronic kidney disease remain largely unknown. This Special Issue provides insights into comorbidities in CKD patients, mainly focused on increased cardiovascular risk, and summarizes current knowledge of underlying pathophysiological mechanisms.
517   $aComorbidities in Chronic Kidney Disease 
606   $aMedicine$2bicssc
610   $aarterial stiffness
610   $acarotid?femoral pulse wave velocity
610   $ahemodialysis
610   $ap-cresyl sulfate
610   $auremic toxins
610   $aarterial calcification
610   $alipid metabolism
610   $ainflammation
610   $acoagulation
610   $aendothelial dysfunction
610   $aepigenetics
610   $achronic kidney disease
610   $auremic cardiopathy
610   $aleft ventricular hypertrophy
610   $aphosphate
610   $aPTH
610   $aFGF23
610   $aklotho
610   $asclerostin
610   $achronodisruption
610   $achronodisruptor
610   $acircadian rhythm
610   $ainternal clock
610   $auremia
610   $auremic cardiomyopathy
610   $aorgan crosstalk
610   $acardiorenal syndrome
610   $aleft-ventricular hypertrophy
610   $aheart failure
610   $acardiac fibrosis
610   $acardiovascular disease
610   $avascular calcification
610   $aexperimental rodent models
610   $aFGFG23
610   $aKlotho
610   $aWnt/?-catenin
610   $aCKD
610   $aparathyroid hormone
610   $asecondary hyperparathyroidism
610   $auremic toxin
610   $aageing
610   $aend-stage kidney disease
610   $apremature ageing
610   $asenescence
610   $abone
610   $agut
610   $acardiovascular
610   $aCKD?MBD
610   $acomorbidity
610   $afibrosis
610   $acalcification
615  7$aMedicine
700   $aJankowski$b Joachim$4edt$01332367
702   $aNoels$b Heidi$4edt
702   $aJankowski$b Joachim$4oth
702   $aNoels$b Heidi$4oth
906   $aBOOK
912   $a9910557705903321
996   $aComorbidities in Chronic Kidney Disease (CKD)$93040895
997   $aUNINA